Enhanced Recovery After Surgery in Extremity Sarcoma
Part of paid clinical trials in Nashville, Tennessee.
- Sponsor
- Joshua Lawrenz
- Study ID
- NCT04461171
- Status
- Recruiting
Conditions
- Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Enhanced Recovery After Surgery — PROCEDUREUndergo an enhanced recovery after surgery program
Study Details
The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.
Key Dates
- Start date
- Dec 14, 2020
- Status verified
- Jul 2024
- Primary completion
- Dec 31, 2025
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: ERASAdministration of a perioperative non-narcotic, multimodal pain management pathway.
- No Intervention: Non-ERAS (Conventional)Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
Primary Outcome Measure
Pain scores [ Time Frame: 3 months ]
Central Contacts
- Vanderbilt-Ingram Service for Timely Access800-811-8480
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Joshua M Lawrenz, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Nashville, TN
By research site
Related Studies
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruiting · Alliance for Clinical Trials in Oncology · Anchorage, Alaska
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruiting · Adela, Inc · Duarte, California
- Cohort to Augment the Understanding of Sarcoma Survivorship Across the LifespanRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
- First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsPHASE1 · Recruiting · Daiichi Sankyo · Boston, Massachusetts